199 related articles for article (PubMed ID: 16461303)
1. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
Yaccoby S; Wezeman MJ; Zangari M; Walker R; Cottler-Fox M; Gaddy D; Ling W; Saha R; Barlogie B; Tricot G; Epstein J
Haematologica; 2006 Feb; 91(2):192-9. PubMed ID: 16461303
[TBL] [Abstract][Full Text] [Related]
2. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.
Pennisi A; Ling W; Li X; Khan S; Wang Y; Barlogie B; Shaughnessy JD; Yaccoby S
PLoS One; 2010 Dec; 5(12):e15233. PubMed ID: 21188144
[TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
[TBL] [Abstract][Full Text] [Related]
4. The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.
Kassen D; Moore S; Percy L; Herledan G; Bounds D; Rodriguez-Justo M; Croucher P; Yong K
Br J Haematol; 2014 Oct; 167(2):194-206. PubMed ID: 25079197
[TBL] [Abstract][Full Text] [Related]
5. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
Ge Y; Zhan F; Barlogie B; Epstein J; Shaughnessy J; Yaccoby S
Br J Haematol; 2006 Apr; 133(1):83-92. PubMed ID: 16512833
[TBL] [Abstract][Full Text] [Related]
7. Co-culture of canine mesenchymal stem cells with primary bone-derived osteoblasts promotes osteogenic differentiation.
Csaki C; Matis U; Mobasheri A; Shakibaei M
Histochem Cell Biol; 2009 Feb; 131(2):251-66. PubMed ID: 18941769
[TBL] [Abstract][Full Text] [Related]
8. [Effect of osteogenically and adipogenically differentiated bone mesenchymal stem cells from mouse on osteoclast formation].
Zhu H; Liu YL; Chen JD; Li H; Liu YX; Xu FF; Jiang XX; Zhang Y; Mao N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1187-90. PubMed ID: 23114145
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.
Li X; Ling W; Khan S; Yaccoby S
J Bone Miner Res; 2012 Aug; 27(8):1635-48. PubMed ID: 22460389
[TBL] [Abstract][Full Text] [Related]
10. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
Yaccoby S; Ling W; Zhan F; Walker R; Barlogie B; Shaughnessy JD
Blood; 2007 Mar; 109(5):2106-11. PubMed ID: 17068150
[TBL] [Abstract][Full Text] [Related]
11. Role of decorin in the antimyeloma effects of osteoblasts.
Li X; Pennisi A; Yaccoby S
Blood; 2008 Jul; 112(1):159-68. PubMed ID: 18436739
[TBL] [Abstract][Full Text] [Related]
12. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
[TBL] [Abstract][Full Text] [Related]
13. Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.
Kassen D; Lath D; Lach A; Evans H; Chantry A; Rabin N; Croucher P; Yong KL
Br J Haematol; 2016 Jan; 172(1):64-79. PubMed ID: 26767468
[TBL] [Abstract][Full Text] [Related]
14. Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival.
Lo CH; Shay G; McGuire JJ; Li T; Shain KH; Choi JY; Fuerst R; Roush WR; Knapinska AM; Fields GB; Lynch CC
Cancer Res; 2021 May; 81(9):2415-2428. PubMed ID: 33526510
[TBL] [Abstract][Full Text] [Related]
15. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
[TBL] [Abstract][Full Text] [Related]
16. A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer.
Rabin N; Kyriakou C; Coulton L; Gallagher OM; Buckle C; Benjamin R; Singh N; Glassford J; Otsuki T; Nathwani AC; Croucher PI; Yong KL
Leukemia; 2007 Oct; 21(10):2181-91. PubMed ID: 17657224
[TBL] [Abstract][Full Text] [Related]
17. Collagen barrier membranes decrease osteoclastogenesis in murine bone marrow cultures.
Agis H; Magdalenko M; Stögerer K; Watzek G; Gruber R
Clin Oral Implants Res; 2010 Jun; 21(6):656-61. PubMed ID: 20337667
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.
Xu S; Menu E; De Becker A; Van Camp B; Vanderkerken K; Van Riet I
Stem Cells; 2012 Feb; 30(2):266-79. PubMed ID: 22102554
[TBL] [Abstract][Full Text] [Related]
19. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.
Li X; Ling W; Pennisi A; Wang Y; Khan S; Heidaran M; Pal A; Zhang X; He S; Zeitlin A; Abbot S; Faleck H; Hariri R; Shaughnessy JD; van Rhee F; Nair B; Barlogie B; Epstein J; Yaccoby S
Stem Cells; 2011 Feb; 29(2):263-73. PubMed ID: 21732484
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
